511 filings
Page 3 of 26
8-K
1tew1ouam bf
20 Oct 22
Termination of a Material Definitive Agreement
4:31pm
8-K
i4gylp20g9ydqtnk3p0t
27 Sep 22
Departure of Directors or Certain Officers
8:45am
8-K
gs87ktbcoy
13 Sep 22
Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML
9:16am
8-K
xbw2345d
19 Aug 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:30am
S-8
eaimxqnhaqc126a
11 Aug 22
Registration of securities for employees
5:10pm
8-K
6er00ybp3ews2wyng7
11 Aug 22
Marker Therapeutics Reports Q2 2022 Operating and Financial Results
4:41pm
8-K
kigl4pq
4 Aug 22
Company expects to initiate Phase 1 trial of MT-601 in r/r NHL in 2023
4:50pm
8-K
3ia2890wbs xv2wjnu
27 May 22
Amendments to Articles of Incorporation or Bylaws
4:06pm
8-K
acngk
13 May 22
Marker Therapeutics Reports Q1 2022 Operating and Financial Results
7:11am
8-K
g4t6rs
26 Apr 22
Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf
7:24am
8-K
c0bk3aa xwcuai7gbfz
6 Apr 22
Departure of Directors or Certain Officers
4:08pm
424B5
xm762nxje aj4jcfq
18 Mar 22
Prospectus supplement for primary offering
5:22pm
8-K
f5qtc
17 Mar 22
Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results
6:21pm
8-K
26d xl0qmt45v4lt
18 Feb 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm